Wednesday, February 08, 2012
 
 
  Home arrow Current Headlines arrow STDs/STIs arrow STDs - esp Herpes II -- Associated with Prostate Cancer (EBP Study, 2009)
Main Menu
Home
About Us
Current Headlines
Abortion
Abstinence
Birth Control
End of Life / Euthanasia
Medical Research
Medical Students
Population
Position Statements
Pregnancy/Development
STDs
Stem Cells & Cloning
Contact Us
Web Links
Site Index
Resources
Related Items
Translator
Quotes to Note

Professor Joel Brind and his colleagues reported a "30% greater chance of developing breast cancer" in their 1996 review and meta-analysis of worldwide data.  

Brind said recently:  

"If we take the overall risk of breast cancer among women to be about 10% (not counting abortion), and raise it by the 30%, we get a 13% lifetime risk.

"Using the 50 million abortions since Roe v. Wade figure, we get 1.5 million excess cases of breast cancer.

"At an average mortality of 20% since 1973, that would mean that legal abortion has resulted in some 300,000 additional deaths due to breast cancer since Roe v. Wade."

Brind said his estimate excludes deaths from the use of abortion to delay first full term pregnancies - a recognized breast cancer risk. 

 
STDs - esp Herpes II -- Associated with Prostate Cancer (EBP Study, 2009) PDF Print E-mail

Sexually Transmitted Infections, especially Herpes II, and Prostate Cancer among Men in the U.S. Military
a statistically significant association between prostate cancer and serologic evidence of HSV-2 infection was detected in the earlier sample (odds ratio, 1.60; 95% confidence interval, 1.05-2.44).

The strength of this association increased when analyses were restricted to sera collected at least 60 months before diagnosis (odds ratio, 2.04; 95% confidence interval, 1.26-3.29; 204 pairs).

If this association is causal, then our findings would suggest a long latency period for prostate cancer development after HSV-2 infection...

 

Abstract
Studies of self-reported sexually transmitted infections (STI) suggesting an association with prostate cancer may reflect underreporting of such infections among nondiseased subjects. To reduce such bias, we studied archived sera in a cohort of U.S. military personnel known to have high rates of both STIs and prostate cancer. Using a nested case-control design, serum samples from 534 men who served on active duty between September 1, 1993 and September 1, 2003 were examined. Controls were individually matched to cases based on date of serum collection, date of birth, branch of service, military rank, marital status, and race. Each of the 267 case-control pairs had two serum samples: a recent serum sample, taken ∼1 year before the case's prostate cancer diagnosis, and an earlier serum sample, taken ∼8 years before diagnosis. Each serum specimen was studied for antibodies against human papillomavirus, herpes simplex virus-2 (HSV-2), and Chlamydia trachomatis. Logistic regression accounted for matching and potential confounding factors.

Study data indicated no association between prostate cancer and serologic evidence of infections just before the reference date.

However, a statistically significant association between prostate cancer and serologic evidence of HSV-2 infection was detected in the earlier sample (odds ratio, 1.60; 95% confidence interval, 1.05-2.44).

The strength of this association increased when analyses were restricted to sera collected at least 60 months before diagnosis (odds ratio, 2.04; 95% confidence interval, 1.26-3.29; 204 pairs).

If this association is causal, then our findings would suggest a long latency period for prostate cancer development after HSV-2 infection. (Cancer Epidemiol Biomarkers Prev 2009;18(10):2665–71)
http://cebp.aacrjournals.org/content/18/10/2665.abstract

 

 

 

 

1. Leslie K. Dennis1,
   2. Julie A. Coughlin1,
   3. Brittany C. McKinnon1,
   4. Timothy S. Wells2,
   5. Charlotte A. Gaydos3,
   6. Eva Hamsikova4 and
   7. Gregory C. Gray1

      1Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa; 2Air Force Research Laboratory, Wright-Patterson Air Force Base, Dayton, Ohio; 3Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland; and 4Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

 
< Prev   Next >

Current News

Go to top of page  Home | About Us | Current Headlines | Abortion | Abstinence | Birth Control | End of Life / Euthanasia | Medical Research | Medical Students | Population | Position Statements | Pregnancy/Development | STDs | Stem Cells & Cloning | Contact Us | Web Links | Site Index | Resources |
 
PhysiciansForLife.org Copyright (C) 2004-2012 All Rights Reserved